Why Juno Therapeutics Shares Jumped 12% In September

Optimism that Juno Therapeutics could have a drug on the market in the next two years boosted shares last month.

Todd Campbell
Todd Campbell
Oct 11, 2015 at 12:40PM
Health Care

Juno Therapeutics (NASDAQ:JUNO) is developing next-generation cancer therapies that use a patient's own immune system to find and destroy cancer cells.

Although the company doesn't have any drugs currently on the market, it hopes that a promising drug for adult lymphoblastic leukemia will succeed in mid stage studies and clear the way to an FDA filling in 2017.

Given high response rates to its most advanced drug and a timeline that could mean Juno Therapeutics begins generating sales within two years, investors boosted shares by 12.1% last month. In the following slideshow, I offer up additional insight into Juno Therapeutics intriguing approach and its timeline to commercialization. 

Why Juno Therapeutics Jumped 12% in September from The Motley Fool